ES514579A0 - Procedimiento para la obtencion de derivados de imidazol trisustituidos. - Google Patents

Procedimiento para la obtencion de derivados de imidazol trisustituidos.

Info

Publication number
ES514579A0
ES514579A0 ES514579A ES514579A ES514579A0 ES 514579 A0 ES514579 A0 ES 514579A0 ES 514579 A ES514579 A ES 514579A ES 514579 A ES514579 A ES 514579A ES 514579 A0 ES514579 A0 ES 514579A0
Authority
ES
Spain
Prior art keywords
trisustituted
procedure
obtaining
imidazole derivatives
imidazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES514579A
Other languages
English (en)
Other versions
ES8306119A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of ES8306119A1 publication Critical patent/ES8306119A1/es
Publication of ES514579A0 publication Critical patent/ES514579A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
ES514579A 1980-07-25 1982-07-30 Procedimiento para la obtencion de derivados de imidazol trisustituidos. Granted ES514579A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH571580 1980-07-25

Publications (2)

Publication Number Publication Date
ES8306119A1 ES8306119A1 (es) 1983-05-16
ES514579A0 true ES514579A0 (es) 1983-05-16

Family

ID=4298165

Family Applications (8)

Application Number Title Priority Date Filing Date
ES504257A Expired ES8301472A1 (es) 1980-07-25 1981-07-24 Procedimiento para la obtencion de derivados de imidazol trisustituidos
ES514583A Granted ES514583A0 (es) 1980-07-25 1982-07-30 Procedimiento para la obtencion de derivados de imidazol trisustituidos.
ES514584A Granted ES514584A0 (es) 1980-07-25 1982-07-30 Procedimiento para la obtencion de derivados de imidazol trisustituidos.
ES514580A Expired ES8306120A1 (es) 1980-07-25 1982-07-30 Procedimiento para la obtencion de derivados de imidazol trisustituidos.
ES514581A Expired ES8306121A1 (es) 1980-07-25 1982-07-30 Procedimiento para la obtencion de derivados de imidazol trisustituidos.
ES514579A Granted ES514579A0 (es) 1980-07-25 1982-07-30 Procedimiento para la obtencion de derivados de imidazol trisustituidos.
ES514582A Granted ES514582A0 (es) 1980-07-25 1982-07-30 Procedimiento para la obtencion de derivados de imidazol trisustituidos.
ES514585A Granted ES514585A0 (es) 1980-07-25 1982-07-30 Procedimiento para la obtencion de derivados de oxazol trisustituidos.

Family Applications Before (5)

Application Number Title Priority Date Filing Date
ES504257A Expired ES8301472A1 (es) 1980-07-25 1981-07-24 Procedimiento para la obtencion de derivados de imidazol trisustituidos
ES514583A Granted ES514583A0 (es) 1980-07-25 1982-07-30 Procedimiento para la obtencion de derivados de imidazol trisustituidos.
ES514584A Granted ES514584A0 (es) 1980-07-25 1982-07-30 Procedimiento para la obtencion de derivados de imidazol trisustituidos.
ES514580A Expired ES8306120A1 (es) 1980-07-25 1982-07-30 Procedimiento para la obtencion de derivados de imidazol trisustituidos.
ES514581A Expired ES8306121A1 (es) 1980-07-25 1982-07-30 Procedimiento para la obtencion de derivados de imidazol trisustituidos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES514582A Granted ES514582A0 (es) 1980-07-25 1982-07-30 Procedimiento para la obtencion de derivados de imidazol trisustituidos.
ES514585A Granted ES514585A0 (es) 1980-07-25 1982-07-30 Procedimiento para la obtencion de derivados de oxazol trisustituidos.

Country Status (23)

Country Link
US (1) US4447431A (es)
EP (1) EP0045081B1 (es)
JP (1) JPS5756466A (es)
KR (13) KR850000883B1 (es)
AR (1) AR230269A1 (es)
AT (1) ATE17349T1 (es)
AU (2) AU7340481A (es)
CA (1) CA1175431A (es)
DD (2) DD201677A5 (es)
DE (1) DE3173434D1 (es)
DK (1) DK331881A (es)
ES (8) ES8301472A1 (es)
FI (1) FI812326L (es)
GB (1) GB2080805B (es)
GR (1) GR75287B (es)
IE (1) IE52071B1 (es)
IL (1) IL63410A (es)
NO (1) NO812542L (es)
NZ (1) NZ197828A (es)
PL (8) PL237000A1 (es)
PT (1) PT73424B (es)
SU (8) SU1235454A3 (es)
ZA (1) ZA815078B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2123831B (en) * 1981-07-20 1986-01-15 Ciba Geigy Ag Trisubstituted oxazo compounds
EP0084756A1 (de) * 1982-01-22 1983-08-03 Ciba-Geigy Ag Trisubstituierte Oxazaverbindungen
FR2633291B1 (fr) * 1988-06-27 1990-09-07 Oreal Derives d'hydroxy-4 isoxazoles, leur procede de preparation et compositions cosmetiques et pharmaceutiques les contenant
US5252322A (en) * 1989-09-22 1993-10-12 The Gillette Company Skin tanning compositions containing imidazoles
NZ239161A (en) * 1990-07-31 1994-01-26 Smithkline Beecham Corp Substituted [1h-imidazol-5-yl] alkanoic acid derivatives; medicaments,
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
MX9300141A (es) * 1992-01-13 1994-07-29 Smithkline Beecham Corp Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5593991A (en) * 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
US5670527A (en) * 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
WO1995013067A1 (en) * 1993-11-08 1995-05-18 Smithkline Beecham Corporation Oxazoles for treating cytokine mediated diseases
US5723477A (en) * 1994-11-10 1998-03-03 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5658903A (en) * 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US6369068B1 (en) 1995-06-07 2002-04-09 Smithkline Beecham Corporation Amino substituted pyrimidine containing compounds
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
ZA9610687B (en) * 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
AP9700912A0 (en) 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
NZ327044A (en) * 1996-01-11 2000-01-28 Smithkline Beecham Corp Substituted imidazole compounds
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
EP0889888A4 (en) * 1996-03-25 2003-01-08 Smithkline Beecham Corp NEW TREATMENT OF LESIONS IN THE CENTRAL NERVOUS SYSTEM
EP0956018A4 (en) 1996-08-21 2000-01-12 Smithkline Beecham Corp IMIDAZOLE COMPOUNDS, COMPOSITIONS CONTAINING THEM AND THEIR USE
US5929076A (en) * 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
HUP0002842A3 (en) * 1997-04-24 2002-01-28 Ortho Mcneil Pharm Inc Substituted imidazoles, process for producing them, pharmaceutical compositions containing them, their use and their intermediates
EP1023066A4 (en) 1997-06-13 2001-05-23 Smithkline Beecham Corp NEW PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUND
US6610695B1 (en) 1997-06-19 2003-08-26 Smithkline Beecham Corporation Aryloxy substituted pyrimidine imidazole compounds
AR016294A1 (es) * 1997-07-02 2001-07-04 Smithkline Beecham Corp Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion
US7301021B2 (en) * 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
US6251914B1 (en) 1997-07-02 2001-06-26 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
WO1999017776A1 (en) 1997-10-08 1999-04-15 Smithkline Beecham Corporation Novel cycloalkenyl substituted compounds
JP2001526230A (ja) 1997-12-19 2001-12-18 スミスクライン・ビーチャム・コーポレイション ヘテロアリール置換イミダゾール化合物、その医薬組成物および使用
PL344330A1 (en) * 1998-05-22 2001-10-22 Smithkline Beecham Corp Novel 2-alkyl substituted imidazole compounds
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
DE69917296T2 (de) * 1998-08-20 2005-05-25 Smithkline Beecham Corp. Neue substituierte triazolverbindungen
US6548503B1 (en) 1998-11-04 2003-04-15 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
WO2000029399A1 (en) * 1998-11-12 2000-05-25 Boehringer Ingelheim (Canada) Ltd. Antiherpes compounds
US6239279B1 (en) 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
JP2003514906A (ja) 1999-11-22 2003-04-22 スミスクライン ビーチャム パブリック リミテッド カンパニー イミダゾール誘導体およびｒａｆキナーゼ阻害剤としてのその使用
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
US7053098B1 (en) 1999-11-23 2006-05-30 Smithkline Beecham Corporation 3,4-Dihydro-(1H) quinazolin-2-one compounds as CSBP/P38 kinase inhibitors
DE60015599T2 (de) 1999-11-23 2005-11-03 Smithkline Beecham Corp. 3,4-DIHYDRO-(1H)CHINAZOLIN-2-ON-VERBINDUNGEN ALS CSBP/p38-KINASE-INHIBITOREN
AU1782301A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p39 kinase inhibitors
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
EP1263753B1 (en) * 2000-03-06 2004-05-06 SmithKline Beecham plc Imidazol derivatives as raf kinase inhibitors
IL155367A0 (en) * 2000-10-23 2003-12-23 Smithkline Beecham Corp NOVEL 2,4,8-TRISUBSTITUTED-8h-PYRIDO[2,3,-d]PYRIMIDIN-7-ONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, PROCESSES FOR THE PREPARATION THEREOF, AND USE THEREOF IN THE PREPARATION OF MEDICAMENTS FOR TREATING CSBP/p38 KINASE MEDIATED DISEASES
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
WO2003022837A1 (en) * 2001-09-05 2003-03-20 Smithkline Beecham P.L.C. Heterocycle-carboxamide derivatives as raf kinase inhibitors
TW200505446A (en) * 2003-01-17 2005-02-16 Fuj Isawa Pharmaceutical Co Ltd Inhibitor of cox
EP1620406A2 (en) * 2003-05-08 2006-02-01 Astellas Pharma Inc. 1,2-diarylimidazoles useful as inhibitors of cox
US7479558B2 (en) * 2005-03-25 2009-01-20 Glaxo Group Limited Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives
PE20100737A1 (es) * 2005-03-25 2010-11-27 Glaxo Group Ltd Nuevos compuestos
WO2013049272A2 (en) * 2011-09-29 2013-04-04 Theraceutix, Llc Composition and method for treatment of symptoms associated with various skin conditions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558645A (en) * 1968-07-08 1971-01-26 Sandoz Ag 2-(4-(4',5-diphenyl - 2 - imidazolyl)-phenoxy) lower aliphatic monocarboxylic acids
CH561718A5 (es) * 1971-05-10 1975-05-15 Ciba Geigy Ag
GB1469532A (en) * 1973-06-28 1977-04-06 Dumex Ltd As Imimdazolyl-alkanoic acid derivatives
US4372964A (en) * 1980-10-30 1983-02-08 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-1H-imidazole-2-methanols

Also Published As

Publication number Publication date
KR850000892B1 (ko) 1985-06-26
AU5655586A (en) 1986-09-11
KR850002744A (ko) 1985-05-15
EP0045081A2 (de) 1982-02-03
PT73424B (en) 1983-06-20
SU1227112A3 (ru) 1986-04-23
FI812326L (fi) 1982-01-26
KR850002750A (ko) 1985-05-15
KR850000886B1 (ko) 1985-06-26
KR850000888B1 (ko) 1985-06-26
DD201677A5 (de) 1983-08-03
AU7340481A (en) 1982-01-28
ES8307245A1 (es) 1983-07-01
KR850000883B1 (ko) 1985-06-26
KR850000884B1 (ko) 1985-06-26
KR850002752A (ko) 1985-05-15
SU1152520A3 (en) 1985-04-23
IE52071B1 (en) 1987-06-10
ES504257A0 (es) 1982-12-01
SU1205764A3 (ru) 1986-01-15
NO812542L (no) 1982-01-26
US4447431A (en) 1984-05-08
JPS5756466A (en) 1982-04-05
ES514585A0 (es) 1983-07-01
ATE17349T1 (de) 1986-01-15
ES8306123A1 (es) 1983-05-16
KR850000885B1 (ko) 1985-06-26
KR850002745A (ko) 1985-05-15
GR75287B (es) 1984-07-13
ES514580A0 (es) 1983-05-16
KR850002746A (ko) 1985-05-15
IE811680L (en) 1982-01-25
DD202554A5 (de) 1983-09-21
KR850002753A (ko) 1985-05-15
PL237002A1 (en) 1983-02-28
ES514581A0 (es) 1983-05-16
SU1145928A3 (ru) 1985-03-15
PL237000A1 (en) 1983-02-28
KR850000873B1 (ko) 1985-06-22
AR230269A1 (es) 1984-03-01
ES514583A0 (es) 1983-05-16
PL237005A1 (en) 1983-02-28
ES8306124A1 (es) 1983-05-16
KR830006230A (ko) 1983-09-20
GB2080805A (en) 1982-02-10
ES8306122A1 (es) 1983-05-16
KR850002748A (ko) 1985-05-15
PT73424A (en) 1981-08-01
CA1175431A (en) 1984-10-02
KR850002755A (ko) 1985-05-15
KR850000891B1 (ko) 1985-06-26
KR850001064B1 (ko) 1985-07-25
KR850000911B1 (ko) 1985-06-27
NZ197828A (en) 1985-11-08
PL237003A1 (en) 1983-02-28
PL237001A1 (en) 1983-02-28
IL63410A0 (en) 1981-10-30
PL135822B1 (en) 1985-12-31
ES514584A0 (es) 1983-05-16
DE3173434D1 (en) 1986-02-20
ES514582A0 (es) 1983-05-16
ES8306119A1 (es) 1983-05-16
DK331881A (da) 1982-01-26
PL237004A1 (en) 1983-02-28
GB2080805B (en) 1984-03-07
KR850002747A (ko) 1985-05-15
SU1205763A3 (ru) 1986-01-15
SU1138023A3 (ru) 1985-01-30
IL63410A (en) 1986-04-29
EP0045081B1 (de) 1986-01-08
KR850000890B1 (ko) 1985-06-26
ES8306121A1 (es) 1983-05-16
SU1169534A3 (ru) 1985-07-23
ZA815078B (en) 1982-07-28
KR850000887B1 (ko) 1985-06-26
KR850002749A (ko) 1985-05-15
ES8306120A1 (es) 1983-05-16
KR850002754A (ko) 1985-05-15
ES8301472A1 (es) 1982-12-01
SU1235454A3 (ru) 1986-05-30
EP0045081A3 (en) 1982-04-07
PL232352A1 (es) 1982-12-20
KR850000889B1 (ko) 1985-06-26
PL236997A1 (en) 1983-01-03
KR850002756A (ko) 1985-05-15

Similar Documents

Publication Publication Date Title
ES514579A0 (es) Procedimiento para la obtencion de derivados de imidazol trisustituidos.
ES523709A0 (es) Procedimiento para la preparacion de derivados de imidazol.
AR223315A1 (es) Procedimiento para la fabricacion de derivados de 2-guanidin-(tiazol o imidazol)
ES513228A0 (es) Un procedimiento para la preparacion de una composicion de derivados del imidazol.
ES504791A0 (es) Procedimiento para la preparacion de derivados de caprolactama.
ES528181A0 (es) Procedimiento para la obtencion de derivados de imidazol (i,5-a)-piridina
ES498208A0 (es) Procedimiento para la obtencion de derivados de triazolilfe-nacil-piridil-eter, de efecto fungicida
ES515031A0 (es) Procedimiento para la obtencion de derivados de azolil-fenoxisustituidos.
ES510875A0 (es) Un procedimiento para la preparacion de un derivado del imidazol.
ES518272A0 (es) Procedimiento para la preparacion de derivados de tiazolina.
ES511317A0 (es) Procedimiento para preparar derivados de imidazol.
ES513392A0 (es) Procedimiento para la obtencion de derivados de 2-amino-piridina sustituidos.
ES537959A0 (es) Procedimiento para preparar derivados de imidazol.
ES498364A0 (es) Un procedimiento para la preparacion de derivados del imidazol.
ES513169A0 (es) Procedimiento para la obtencion de nuevos derivados de benzazol.
ES514481A0 (es) Procedimiento para la obtencion de derivados de diaril-imidazol.
ES502162A0 (es) Procedimiento para la obtencion de derivados del imidazol.
ES530042A0 (es) Procedimiento para la obtencion de derivados de imidazol conteniendo azufre
ES506911A0 (es) Procedimiento para la obtencion de derivados pirazolicos de la oximinociano-acetamida de efecto fungicida.
ES539306A0 (es) Procedimiento para preparar derivados de imidazol con actividad antitrombotica.
ES501700A0 (es) Procedimiento para la preparacion de derivados de imidazol
ES522859A0 (es) Procedimiento para la obtencion de derivados de trifluormetilfenoxi-fenilo.
MX6968E (es) Procedimiento para preparar salicilato de imidazol
ES523287A0 (es) Procedimiento para la obtencion de hidantoinas n-sulfeniladas.
ES519843A0 (es) Procedimiento para la obtencion de derivados de tetrahicro-2 pirimidona metil-sustituidos.